Table 2.

Clinical observation of the mice injected with SNPs at indicated doses. Time of death, significant decrease in animal weight and signs of morbidity for the mice mentioned in Table 1 are described here.

Clinical Observation
Time	Nanoparticles	Female			Male
		Time of Death	Weight Loss	Morbidity	Time of Death	Weight Loss	Morbidity
10 days	Stöber SNPs50 (ID > MTD)	5-24 hr post-injection	NO	NO	6-24 hr post-injection	Up to 11%	NO
	Mesoporous SNPs500 (ID > MTD)	2-3 days post-injection	Up to 10%	Signs of moderate pain for example: hunched posture, rough hair, slow movements	1-3 days post-injection	Up to 6%	Signs of moderate pain for example: shivering, sunken eye, rough hair.
	Stöber SNPs500 (ID > MTD)	24 hr post-injection	Up to 24%	Signs of severe pain for example: shivering, rough hair, slow movements, weakness, blindness, hemiplegia, paralysis, necrosis at the end of tail, violent reaction to stimuli or when approached, non-responsive when coaxed, ataxia and pacing around in circles, changes in respiration	24 hr post-injection	Up to 16.14%	Signs of severe pain for example: shivering, sensitive to handling, back leg weakness and rigidity, very rough hair, squinted and sunken eye, violent reactions or non-responsive to stimuli or when approached, non-responsive when coaxed, ataxia and circling, changes in respiration, hemiplegia
	Stöber SNPs50 (MTD)	No significant clinical abnormalities were observed.			No significant clinical abnormalities were observed.
	Mesoporous SNPs500 (MTD)
	Stöber SNPs500 (MTD)
60 days	Stöber SNPs50 (MTD)	No significant clinical abnormalities were observed.			No significant clinical abnormalities were observed.
	Mesoporous SNPs500 (MTD)
	Stöber SNPs500 (MTD)
180 days	Stöber SNPs50 (MTD)	No significant clinical abnormalities were observed.			No significant clinical abnormalities were observed.
	Mesoporous SNPs500 (MTD)
	Stöber SNPs500 (MTD)